MedTrace Logo

Clinical Efficacy and Safety Assessment of Alsareen Capsule for the Management of H. Pylori Infection

NCT06304532 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2024-03-13

No results posted yet for this study

Summary

Helicobacter pylori infection is a major cause of morbidity and mortality worldwide. More than 50% of the global population is estimated to be infected. In 2015, there were approximately 4.4 billion individuals with H pylori infection worldwide. In Pakistan the prevalence of H. pylori infection, highest (63%) in middle age (41-60 years) group while lowest (33%) in teens and pre-teens (\<20 years) group. In young age (20-40) and old age (\>60 years) groups, the prevalence of H. pylori was 55% and 60% respectively.

In conventional system of medicine H. pylori infection is treated by triple regimen antibiotic therapy that are amoxicillin, clarithromycin and metronidazole along with acid reducing proton pump inhibitor. Due to recurrence of infection this therapy is repeated multiple times resulting in drug resistance and long term side effects. These side effects \& a long term impact of H. pylori in patient general health necessitates development of a safe and long term effective therapy.

Conditions

  • H. Pylori Infection

Sponsors & Collaborators

  • Hamdard University

    lead OTHER

Principal Investigators

  • Syed Zahoor Zaidi · Hamdard University

Eligibility

Min Age
15 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2024-03-05
Completion
2024-03-06

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06304532 on ClinicalTrials.gov